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Abstract We have characterized, by RT-PCR amplification 
using specific primers, the presence of glucagon-like peptide-I 
(GLP-I) receptor mRNA in CA-77 cells, a C cell line derived 
from a rat medullary thyroid carcinoma. Down-regulation of the 
GLP-1 receptor mRNA was observed after exposure of CA-77 C 
cells with GLP-1 (7-37). Increased secretion of both calcitonin 
gene-related peptide (CGRP) and calcitonin (CT) occurred after 
treatment with GLP-1 (7-37) associated with elevated steady- 
state levels of CGRP and CT mRNA. GLP-1 (7-37) increased 
cAMP formation in CA-77 cells in a dose-dependent manner; 
exendin (9-39), a GLP-1 receptor antagonist, inhibited cAMP 
production. The GLP-1 peptide which is produced by intestinal 
cells could be involved in the control of CT secretion through an 
entero-thyroidal xis implying GLP-1 receptor and increased CT 
gene expression. 
Key  words: C-cell; Glucagon-l ike peptide 1; Glucagon-l ike 
peptide 1 receptor mRNA;  Calcitonin mRNA;  Calcitonin 
gene-related peptide mRNA 
1. Introduction 
Glucagon and glucagonqike peptide 1 (GLP-1) are struc- 
turally related peptides arising from the tissue-specific proc- 
essing of preproglucagon. The precursor contains in addit ion 
to glicentin and glucagon the sequences of two glucagon-like 
peptides, GLP-1 and GLP-2, separated by an intervening se- 
quence [1]. The posttranslat ional processing of preprogluca- 
gon differs in pancreas and intestine [2,3]. In the pancreas the 
precursor is processed to glucagon and GLP-1, and in both 
small and large intestines glicentin, GLP-1, GLP-2 and inter- 
vening peptide are found. Three different forms of GLP-1 are 
produced by intestinal L cells, GLP-1 (1 37), GLP-1 (7 36 
amide), and GLP-1 (7-37), but only truncated forms of 
GLP- I  are biologically active [4] as potent insulin secreta- 
gogues. The existence of a gastroentero-thyroidal axis in- 
volved in the control of calcitonin (CT) secretion was postu- 
lated 23 years ago [5]. Glucagon [6] as well as partially 
purified enteroglucagon were shown to stimulate the CT se- 
cretion rate in pigs [5]. We have therefore studied the effects of 
GLP-1 (7-37) on the secretion of CGRP and CT by the CA- 
77 C cell line, and on the steady-state l vel of their mRNAs.  
The effect of GLP- I  (7 37) agonists and antagonists on cAMP 
product ion by CA-77 cells was analysed. We have also char- 
acterized by RT-PCR the presence of GLP-1 receptor mRNA,  
and showed a down-regulation of GLP-1 receptor mRNA 
induced by GLP-1 (7-37). 
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2. Materials and methods 
2. I. Cell culture 
The CA-77 cells were maintained in DMEM/Ham's F10 (1:1) (Gib- 
co/BRL, France) supplemented with 10 gg/ml insulin (Sigma), 
3 x 10 s M sodium selenite (Gibco/BRL, France), 5 gg/ml transferrin 
(Gibco/BRL, France), 110 mg/l sodium pyruvate (Gibco/BRL, 
France), and a mixture of antibiotics (100 units/ml penicillin+100 
gg/ml streptomycin; Gibco/BRL, France). Cells were plated at an 
initial density of 4x 104 cells/cm 2 in a medium containing DMEM/ 
Ham's F10 (1:1), 10% heat-inactivated fetal calf serum (J. Boy, 
Reims, France), 110 mg/l sodium pyruvate, 100 units/ml penicillin, 
and 100 gg/ml streptomycin. After 48 h of plating, the medium was 
changed and replaced by the growth medium described above; the 
growth medium was changed at 48-h intervals. GLP-I (7 37) from 
Peninsula Laboratories Europe Ltd (Merseyside, UK) was dissolved 
in 0.01 N HCI to 10 4 M and then in culture medium to reach 10 -8 
M. Dexamethasone (Sigma), was dissolved in absolute thanol and 
then diluted in PBS to reach a final ethanol concentration of 0.005"/,, 
in the growth medium. Controls with the same volume of vehicle were 
used in each case. Cells were harvested at confluence. 
2.2. RNA extraction, and Northern blot hybridization 
Total RNAs were extracted with guanidium thiocyanate method [7]. 
The RNA pellets were dissolved in sterile distilled water, and quanti- 
fied by optical density at 260 nm. Aliquots of total RNAs were de- 
natured using formaldehyde; they were electrophoresed on 1% agar- 
ose gel [8], and RNAs were transferred to Gene-screen membranes 
(NEN) using 0.025 M phosphate buffer (pH 6.5). 
Hybridizations for the 3 probes (CT, CGRP, and cyclophilin) were 
performed under the same conditions. Membranes were prehybridized 
for 4 h at 42°C in 50% formamide, 0.2% polyvinyl pyrrolidone, 0.2% 
bovine serum albumin, 0.2% Ficoll, 0.05 M Tris-HC1 (pH 7.5), 1 M 
NaCI, 0.1% sodium pyrophosphate, l% sodium dodecyl sulfate (SDS), 
10% dextran sulfate, and denatured salmon sperm DNA (100 gg/ml). 
Hybridization was carried out for 16 h at 42°C in a similar solution 
but depleted of NaCI and dextran sulfate. Labeled probes were added 
to the hybridization solution at 10 ng/ml; cDNA probes were dena- 
tured by heating (100°C for 10 min). Membranes were washed by two 
changes of 2xSSC (I×SSC=0.1 M NaC1, and 0.015 M sodium 
citrate) at room temperature for 5 min, then 2 changes of 2× SSC, 
and 1% SDS at 55°C for 30 min, and finally 2 changes of 0.1 × SSC at 
room temperature for 30 min. Dried membranes were exposed at 
-80°C to Kodak Royal X-Omat AR5 films. Autoradiographs were 
quantified in an automatic densitometer scanner (Shimadzu Scientific 
Instruments). For both probes (CT and CGRP) quantification i - 
volved a correction including the cyclophilin control probe, and 
thus our data were expressed as CT/cyclophilin ratios and CGRP/ 
cyclophilin ratios. 
2.3. Polymerase hain reaction 
cDNA was synthesized from 3 gg of total RNA. The reaction 
mixture had a final volume of 20 p.l, and contained 50 mM KCI, 20 
mM Tris-HCl (pH 8.4), 2.5 mM MgC12, nuclease free BSA (1 mg/ml), 
20 U of RNAsin, 200 U of M-MuLV reverse transcriptase (BRL), 
1 mM of each dNTP and 50 pmol of a 3' oligo dT primer. Annealing 
was performed for 10 min at 23°C and primer extension for 1 h at 
37°C. The reaction was then diluted to 100 gl with the same buffer 
containing 50 pmol of each specific primer and 2.5 units of Taq 
polymerase. Amplification was performed uring 30 cycles: 30 s at 
95°C (denaturation), 30 s at 55°C (annealing) and 30 s at 72°C (ex- 
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tension). Control reactions were performed as follows: positive con- 
trol with total RNA extracted from CA-77 cells and negative ones 
with CA-77 cell total RNA in the absence of reverse transcriptase or
after digestion with RNAase A (1 mg/ml) 1 h at 37°C. 
2.4. Analysis of PCR products 
Amplified products were analysed by electrophoresis in 1.2°/,, agar- 
ose gel, visualized by ethidium bromide, transferred to Nylon mem- 
branes (NEN). The amplified cDNA was hybridized with a specific 
48-mer oligonucleotide probe of the GLP-I receptor cDNA [9] radio- 
labelled with [32P]dCTP using Terminal Deoxynucleotidyl Transferase 
(NEN 3' end labeling system). The membranes hybridized at 42°C in 
presence of 50% formamide were washed as described above. 
2.5. Preparation of :~2 P-labeled probes 
The CT-specific probe was the BglII-NsiI fragment of the human 
CT cDNA. The plasmid containing near full-length uman CT cDNA 
was kindly provided by M.G. Rosenfeld (University of California San 
Diego, La Jolla, CA, USA). Competent XL-I blue cells (Stratagene, 
La Jolla, CA, USA) were transformed by the pUC8 plasmid. Plasmid 
DNA was extracted using the alkaline lysis method and purified by 
ultracentrifugation CsC1 gradient. After enzymatic hydrolysis and 
electrophoresis, the fragment BglII-Nsil was electroeluted from the 
agarose gel, and labeled with [32p]dCTP by nick-translation. The 
CGRP-specific probe was the BamII-EcoRI fragment of the human 
CGRP cDNA. The pUC8 plasmid containing the full length human 
CGRP cDNA was provided by M.G. Rosenfeld, and the probe was 
prepared as previously described for the CT probe. GLP-1 receptor 
insert was cloned in PGEM-T vector (Promega). The fragment of 
insert was PCR amplified using specific oligonucleotides primers sep- 
arated by agarose gel electrophoresis and purified by elution using 'Jet 
Sorb System' (Bioprobe Systems) A cyclophilin mRNA probe was 
used to verify the specificity of the changes occurring in CT and 
CGRP mRNAs. A 48-mer oligonucleotide (Bioprobe System, Mon- 
treuil sous bois, France) specific for the cyclophilin mRNA was 5' 
end-labeled using T4 polynucleotide kinase and [7-32P]ATP, and then 
purified on Sephadex G-50 fine columns. 
2.6. Calcitonin and CGRP contents 
2.6.1. Tissue extraction. Cell culture medium was collected and 
treated as previously described [10] to measure the CT and CGRP 
levels. The peptide contents (CT and CGRP) of C cells were also 
measured by RIAs; therefore, 400 lal 0.1 N HC1 were added to culture 
dishes. Then the cells were scraped off and sonicated for 15 s, allowed 
to stand for 16 h at 4°C, and then frozen at -35°C until assayed. 
2.6.2. Radioimmunoassays (RIAs). The CT RIA was already re- 
ported [11,12]; in brief, the G813 antibody (goat antiserum raised 
against synthetic human CT) was a gift of Dr. H. Heath (Mayo Clinic 
and Mayo Foundation, Rochester, MN, USA), and the detection 
limit of the assay was 3.9 pg per tube. This assay used 125 I-labeled 
human CT and unlabeled synthetic human CT (Ciba-Geigy, Basel, 
Switzerland) as standard; therefore, the results are expressed as ng 
equivalent human CT/mg protein since the protein content of culture 
dishes was determined according to Lowry et al. [13]. Intra-assay 
variations for the CT RIA were 5°/,, and inter-assay variations were 
10%. For the CGRP RIA already described [14,15], we have used 
synthetic human CGRP (Sigma) as standard, a sheep antibody raised 
against synthetic human CGRP diluted 1 : 100 000, and 
[125I]iodohistidyl human CGRP from Amersham (Les Ulis, France). 
The tubes were preincubated for 4 days at 4°C and then incubated for 
3 days at 4°C in the presence of labeled CGRP. The bound and free 
fractions were separated by adding 0.15 ml of dextran choarcal sus- 
pension buffer to each assay tube (0.5 ml); after centrifugation at 
2000×g for 20 min, the supernatant was discarded. The detection 
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Fig. 1. (A) Agarose gel analysis of PCR products. Total RNAs ex- 
tracted from CA-77 C cells were reverse transcribed and amplified 
with specific rat GLP-1 receptor primers. One quarter of the reac- 
tion was electrophoresed. The 1.2% agarose gel contained 2 mg/ml 
ethidium bromide. Lanes 1 5: 1.5, 3, 6, 9, 12 lag of total RNAs. (B) 
Autoradiogram of the Southern blot of PCR products (A) hybrid- 
ized with 32p-radiolabeled rat GLP-1 receptor-specific probe (see 
Table 1). (C) Northern hybridization of 25 lag total RNAs extracted 
from CA-77 C cells treated with 10 s M GLP-1 (7 37), and hybrid- 
ized with the 219 bp PCR product labeled with 32p by random 
priming; the signal was observed after 4 days of exposure. Two 
mRNAs of 2.7 and 3.6 kb were detected (upper side). At the bot- 
tom, hybridization with a control cyclophilin probe. (C) Controls, 
and cells treated from 3 h. 
limit of this assay was l0 pg per tube with intra-assay variations of 
6%, and inter-assay variations of 11%. 
2. 7. Adenylyl cyclase activity assay 
The production of cyclic AMP in CA-77 cells in the absence (con- 
Table 1 
Sequence and localisation of the primers used 
Primers Sequence 5'-3' 
TGTACCTGAGCATAGGCTGG 819 Sense 
TGAGATTAGCCTTCAGCTTGG 1034 Antisense 
GCAAGCGTATGATGAGCCAATAGTTCATGTTGGAGTTCCTGGTCCAGC Probe 903-950 
The primers, and the probe were chosen from the cDNA sequence reported in [9]. 
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Fig. 2. Effects of GLP-1 (7-37) agonists and antagonists on cAMP production by CA-77 C cells. Each point was the mean of duplicates. The 
basal value was 0.68 pmol cAMP/10 ~ cells. TGLP-1, GLP-1 (7-37); tExendin, exendin (9 39). 
trol) or presence ofdifferent peptides was measured by RIA [16] from 
cells treated as previously described [17]. Porcine glucagon was ob- 
tained from Novo Research Institute (Bagsvaerdt, Denmark), and 
porcine oxyntomodulin was a gift from Dr. D. Bataille (INSERM 
Unit 376, Montpellier). Exendin-3, exendin-4, and exendin (9 39) 
were generously provided by Dr. J. Eng (VA Medical Center, Bronx, 
New York, USA). 
2.8. Statistical analysis 
All probabilities were calculated using the Mann-Whitney U-test 
for ranked non-parametric data. All data are presented as the 
mean _+ S.E.M. of four determinations. 
3. Results 
3.1. Identification of  GLP-1 receptor mRNA 
The primers used for amplification of the PCR products are 
reported in Table 1. Gel electrophoresis of RT-PCR amplifi- 
cation products using specific GLP-1 receptor primers re- 
vealed the presence in CA-77 C cells of a single band stained 
by ethidium bromide (Fig. 1A). This band had the correct size 
of 219 bases and gave a strong signal after transfer and hy- 
bridization with a specific rat GLP-1 receptor probe (Fig. 1 B). 
No amplification was observed when the aliquots studied 
were treated with RNAase before reverse transcription and 
amplification (data not shown). 
The presence of rat GLP-1 receptor mRNA in CA-77 C 
cells established by RT-PCR was substantiated by Northern 
blot. When 25 lag of total RNA and the 219 bp fragment 
obtained by PCR amplification was used as probe and labeled 
by random priming, a strong signal was observed after 4 days 
of exposure as two transcripts of 2.7 and 3.6 kb (Fig. 1C). 
3.2. Biological effects of  GLP-1 (7 to 37) 
3.2.1. Effects on cAMP production. The GLP-1 (7 37) 
stimulation of adenylyl cyclase activity has been described as 
a receptor-mediated process requiring a functional coupling to 
GTP-binding proteins [18]. Thus, the effect of GLP-1 agonists 
on adenylyl cyclase activity in Ca-77 cells was investigated to
ascertain the functionality of the GLP-1 receptor. The results 
in Fig. 2 show that all peptides tested with the exception of 
exendin (9-39) stimulated cAMP production. Maximal stimu- 
lation of adenylyl cyclase activity obtained with GLP-I (7- 
37), glucagon, oxyntomodulin, exendin 3, and exendin 4 was 
3.5-8.5-fold over basal values (0.68 pmol cAMP produced/105 
cells). However, 10 .8 M GLP-1 (7 37) was more efficient han 
the same dose of glucagon or oxyntomodulin. GLP-1 (7-37) 
and its agonists exendin-3 and exendin-4 were equipotent 
(Fig. 2). Exendin (9-39) at 10 .6 M, a previously described 
antagonist of GLP-1 receptor, blunted the stimulation of 
cAMP production (Fig. 2) induced by GLP-1 (7-37). 
3.2.2. Effects on both CGRP and CT secretion. CGRP se- 
cretion was clearly increased after short-time incubation of 
CA-77 cells with 10 -s M GLP-1 (7-37). A 2-fold increase in 
the CGRP release in the culture medium was regularly ob- 
served after 1 h of treatment (67.4 + 7.8 vs. 32.8 + 0.6 ng/mg 
protein in controls, P< 0.01), this rise being still maintained 
after 3 h of hormone exposure (Fig. 3). A similar response 
was observed for the CT secretion (332+28 vs. 218+ 12 pg/ 
mg protein in controls after 3 h of treatment, P < 0.05). In all 
experiments performed, the C cell content of both CGRP and 
CT (data not shown) was reduced (-20%) after 3 h of expo- 
sure to 10 -s M GLP-1 (7-37) (Fig. 3). Sensitisation of C cell 
by previous exposure to 10 6 M dexamethasone for 20 h 
changed the induction of neither CT nor CGRP secretions 
after 1 h of treatment with 10 -s M GLP-I (7-37) (412_+40 
vs. 228_+ 32 pg CT/mg protein in controls, P<0.05;  and 
195+30 vs. 112_+22 ng CGRP/mg protein in controls, 
P < 0.05). 
3.2.3. Effects on both CGRP and CT mRNA levels'. An 
increase in the steady-state l vel of CGRP mRNA was ob- 
served from 3 to 48 h after treatment of CA-77 cells with 10 -8 
M GLP-1 (7-37); the ratio CGRP mRNA/cyclophilin mRNA 
was maximally increased in all experiments by a factor of 2 
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Fig. 3. Effects of 10 -8 M GLP-l (7 37) on CGRP secretion, cellular 
content of CGRP, and CGRP mRNA by CA-77 C cells. The results 
were expressed as the ratio CGRP mRNA/cyclophilin mRNA used 
as a control probe. Treated ( ); controls (..-). Means+S.E.M. 
of four culture dishes. *P<0.05, **P<0.01, ***P<0.01 from con- 
trols (C). 
(Fig. 3). As shown in Fig. 3, the increased CGRP and CT 
mRNAs  (0.50+0.08 vs. 0.17+0.04 arbitrary units for CT 
mRNA in controls, P< 0.05) after 16 h of exposure to the 
hormone was associated with a reduction in the cellular con- 




Fig. 4. Northern hybridization of 24 ~tg total RNAs extracted from 
CA-77 C cells treated for 24 h with 10 -s M GLP-1 (7 37). (a) Hy- 
bridization with the 219 bp specific GLP-I receptor probe. (b) Hy- 
bridization with a control cyclophilin probe. (C) Controls. 
in controls, P<0.001)  which can be accounted for by an 
elevated secretion of both peptides. 
3.3. Variations in GLP-1 receptor mRNA 
Exposure of C cells to 10 -6 M dexamethasone elicited small 
changes in GLP-1 receptor mRNA (data not shown); a tran- 
sient increase (+31% after 3 h) occurred followed by a reduc- 
tion of its level ( -28% after 48 h of treatment). Down-regula- 
tion of the rat GLP-I  receptor mRNA was observed after 
treatment of CA-77 C cells with 10 -s M GLP-1 (7-37). An 
80% decrease was observed after 3 h of treatment as the ratio 
of the GLP-1 receptor probe/cyclophilin control probe (Fig. 
1), and a 30% decrease was still evident after 24 h of treatment 
(Fig. 4) (0.49 + 0.04 vs. 0.71 + 0.06 arbitrary units in controls, 
P < 0.05). 
4. Discussion 
Our results demonstrate for the first time the presence of 
GLP-1 receptor mRNA in cells (C cells) which synthesizes 
and produces CT and CGRP peptides by alternative splicing 
of the primary transcript of the CT gene. The specificity of the 
amplified products was directly established by hybridization 
with a rat GLP-1 receptor-specific probe. The messenger ex- 
pressed in CA-77 cells is polyadenylated as we have used oligo 
dT and reverse transcriptase to obtain the first cDNA copy. 
The presence of GLP-1 receptor mRNA was substantiated by 
the positive signal observed with Northern hybridization. As 
in a rat insulinoma cell line (INS-l) [9], two mRNAs of 2.7 
and 3.6 kb could be detected in the rat CA-77 C cell line. 
GLP-1 receptor mRNA expression has been found to be 
highly expressed in both rat and human pancreatic islets 
[19,20]. We found that GLP-1 (7-37) induced a down-regula- 
tion of GLP-1 receptor mRNA in CA-77 C cells. In cultured 
rat pancreatic islets, it was recently reported that GLP-I  re- 
ceptor mRNA levels remained unchanged under all conditions 
that altered intracellular cAMP levels [21]. Our observation 
suggested that regulation of GLP-I  receptor mRNA could be 
different in CA-77 C cells. Glucocorticoids were found to 
change slightly the level of GLP-1 receptor mRNA in CA- 
77 cells, since dexamethasone, after a transient increase, 
down-regulated GLP-1 receptor mRNA levels by approx. 
30%. Our data are in agreement with those in cultured rat 
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pancreatic islets where dexamethasone d creased by 50% after 
48 h the GLP-1 receptor mRNA level [21]. 
The presence of a functional GLP-1 receptor in CA-77 C 
cells was also ascertained by the use of specific agonists and 
antagonists of such a receptor. 
As in the Syrian hamster insulinoma [18], the cAMP pro- 
duction in CA-77 C cells was similarly increased by GLP-1 (7 
37), and the agonists exendin 3 and exendin 4. Moreover, this 
cAMP induction was blunted by exendin (9 39) a specific 
antagonist of GLP-1 receptor [18], and the potency of GLP- 
1 (7 37) was > glucagon > oxyntomodulin. All these results 
indicate the presence of GLP-1 receptors in CA-77 C cells 
coupled to adenylyl cyclase. 
Our results also showed that GLP-1 (7 37) stimulated the 
secretion of both CGRP and CT in C cells since the release in 
the culture medium of both peptides was increased 1 h after 
addition of the hormone. The cellular content of CGRP was 
20% decreased 3 h after continuous exposure to GLP-1 (7 37) 
maybe as a consequence of the elevated secretion. The 
changes in CGRP and CT secretion were associated with al- 
tered levels of CGRP and CT mRNAs.  The steady-state l vel 
of CGRP and CT mRNAs  was increased in face of a drop in 
the cell content of both peptides. This mechanism may be 
viewed as an adaptation to the elevated secretion which re- 
duces the cellular content of CGRP and CT. If cAMP and 
phorbol esters are known to increase CT gene expression 
[22,23], GLP-1 (7 37) is the first hormonal peptide reported 
to increase both CGRP and CT mRNAs.  At this time, GLP-1 
(7-37) is only known as a potent stimulator of insulin secre- 
tion in the presence of glucose [6], this effect being mediated 
by activation of adenylate cyclase and a rise in the intracel- 
lular concentration of cAMP [24]. The secretion of GLP-I  is 
stimulated by carbohydrate intake, the absorption of glucose 
through the sodium/glucose cotransporter stimulates the se- 
cretion of GLP-1 [25]. Our data suggest that GLP-I  could 
be one of the intestinal molecules controlling CT secretion. 
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